Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer.

× No keyword cloud information.

11 in total

Review 1. Use of liposomal doxorubicin for adjuvant chemotherapy of breast cancer in clinical practice.

Authors: Ming Zhao; Xian-Feng Ding; Jian-Yu Shen; Xi-Ping Zhang; Xiao-Wen Ding; Bin Xu
Journal: J Zhejiang Univ Sci B Date: 2017 Jan. Impact factor: 3.066

Review 2. Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review.

Authors: Ricardo Fernandes; Sasha Mazzarello; Brian Hutton; Risa Shorr; Habeeb Majeed; Mohammed Fk Ibrahim; Carmel Jacobs; Michael Ong; Mark Clemons
Journal: Support Care Cancer Date: 2016-05-05 Impact factor: 3.603

3. BP-C1 in the treatment of patients with stage IV breast cancer: a randomized, double-blind, placebo-controlled multicenter study and an additional open-label treatment phase.

Authors: Stig Larsen; Kritiya Butthongkomvong; Alexey Manikhas; Ekaterina Trishkina; Elena Poddubuskaya; Marina Matrosova; Vichien Srimuninnimit; Steen Lindkær-Jensen
Journal: Breast Cancer (Dove Med Press) Date: 2014-11-27

4. Significantly higher pathologic complete response (pCR) after the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: Evidence from a meta-analysis of randomized controlled trials.

Authors: Yu-Tuan Wu; Zhou Xu; Bilal Arshad; Jiu-Song Wu; Ke Zhang; He Wu; Xin Li; Hao Li; Ying-Cun Li; Zhong-Liang Wang; Kai-Nan Wu; Ling-Quan Kong
Journal: J Cancer Date: 2018-08-06 Impact factor: 4.207

Review 5. Anticancer and cardio-protective effects of liposomal doxorubicin in the treatment of breast cancer.

Authors: Yesenia L Franco; Tanaya R Vaidya; Sihem Ait-Oudhia
Journal: Breast Cancer (Dove Med Press) Date: 2018-09-11

Review 6. Efficacy and cardiac safety of the concurrent use of trastuzumab and anthracycline-based neoadjuvant chemotherapy for HER2-positive breast cancer: a systematic review and meta-analysis.

Authors: Yu-Tuan Wu; Zhou Xu; Ke Zhang; Jiu-Song Wu; Xin Li; Bilal Arshad; Ying-Cun Li; Zhong-Liang Wang; Hong-Yuan Li; Kai-Nan Wu; Ling-Quan Kong
Journal: Ther Clin Risk Manag Date: 2018-09-26 Impact factor: 2.423

7. The Efficacy of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Case-Control Study in Taiwan.

Authors: Chih-Chiang Hung; Youngsen Yang; I-Chen Tsai; Chiann-Yi Hsu; Chia-Hua Liu; Jie-Ru Yang
Journal: Biochem Res Int Date: 2020-04-28

8. Primary systemic therapy in HER2-positive operable breast cancer using trastuzumab and chemotherapy: efficacy data, cardiotoxicity and long-term follow-up in 142 patients diagnosed from 2005 to 2016 at a single institution.

Authors: Silvia Antolín; Benigno Acea; Luis Albaina; Ángel Concha; Paz Santiago; Tomás García-Caballero; Joaquín J Mosquera; José Ramón Varela; Rafaela Soler; Lourdes Calvo
Journal: Breast Cancer (Dove Med Press) Date: 2018-12-27

9. Pegylated Liposomal Doxorubicin (Caelyx^®) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial.

Authors: Silvia Dellapasqua; Pamela Trillo Aliaga; Elisabetta Munzone; Vincenzo Bagnardi; Eleonora Pagan; Emilia Montagna; Giuseppe Cancello; Raffaella Ghisini; Claudia Sangalli; Mara Negri; Manuelita Mazza; Monica Iorfida; Anna Cardillo; Angela Sciandivasci; Nadia Bianco; Ana Paula De Maio; Monica Milano; Giuseppe Maria Campennì; Loredana Sansonno; Giuseppe Viale; Anna Morra; Maria Cristina Leonardi; Viviana Galimberti; Paolo Veronesi; Marco Colleoni
Journal: Curr Oncol Date: 2021-12-07 Impact factor: 3.677

10. Effectiveness and safety of pegylated liposomal doxorubicin versus epirubicin as neoadjuvant or adjuvant chemotherapy for breast cancer: a real-world study.

Authors: Jin Zhang; Hongchuan Jiang; Jian Zhang; Guoqiang Bao; Guoqiang Zhang; Haibo Wang; Xi Wang
Journal: BMC Cancer Date: 2021-12-06 Impact factor: 4.430

Phase II study of neoadjuvant pegylated liposomal doxorubicin and cyclophosphamide ± trastuzumab followed by docetaxel in locally advanced breast cancer.